Skip to content

    Announcements

    Exciting News for WebMD Members!

    We've been busy behind the scenes building new message boards for you. You'll have new and easier ways to find messages, connect with others, and share your stories.

    And, this will all be available on your smartphone or other mobile device!

    What Do You Need to Do?

    The message board you're used to will be closing in the coming weeks. While many of your boards will be making the move to our new home, your posts will not. Want to keep a discussion going? Save posts you want to continue (this includes your member profile story), so that you can re-post them in the new message boards.

    Keep an eye here and on your email inbox, we'll be back in touch soon to give you all the information you need!


    Yours in health,
    WebMD Message Boards Management

    Another Cholesterol Drug Fails
    avatar
    bobby75703 posted:
    "Heart drug Tredaptive ineffective."

    The story in full:
    http://www.cbsnews.com/8301-18563_162-57560359/study-heart-drug-tredaptive-is-ineffective/
    Reply
     
    avatar
    iride6606 responded:
    To be fair, this is not really a new drug. It is just extended time release Niacin combined with a new drug to help control flushing which is common with Niacin. The drug was intended to increase HDL. There were many studies that came out over the past couple of years showing that the HDL particles created by Niacin were not effective in binding to LDL particles. Naturally occurring HDL particles were more effective.

    It was common knowledge over a year ago this drug was not going to reach the goals set for it's study. It's not a cholesterol lowering drug, just Niacin.

    What many people don't know is that 92% of drugs that test successfully in lab animals fail in humans, it's the exception that a drug succeeds, the vast majority fail.
     
    avatar
    bobby75703 replied to iride6606's response:
    Right, I understand there is nothing new about using niacin for cholesterol issues, but it represents another failure in the wake of the failed Aim High study. Plus other HDL raising drugs failed recently
    The concept of artificially raising HDL with niacin to prevent heart attacks is officially dead- and buried. The entire HDL theory is falling apart. Its over.

    The lesson to be learned here is no matter how much we believe in something, it can prove to be false decades later.


    I'm willing to bet the LDL "bad" cholesterol theory days are also numbered.
     
    avatar
    farsidexyz replied to bobby75703's response:
    An interesting fact from the "AIM High Trial" is that there were a 233% increase in ischemic strokes for those taking Niacin vs those not taking Niacin.


    http://www.nih.gov/news/health/may2011/nhlbi-26.htm


    From the CBSnews article (link posted by Bobby) -- "More than 25,000 patients at high risk for heart problems took part in the study. Besides being ineffective at preventing heart attacks, Tredaptive caused significant side effects Merck, the maker of Tredaptive, would not specify what those side effects were."



    I wonder what those side effects were?
     
    avatar
    iride6606 replied to bobby75703's response:
    The lesson to be learned here is no matter how much we believe in something, it can prove to be false decades later.



    I think all this shows is that the same drug we knew to ineffective 3 years ago still is. The HDL theory confuses me though. There is no change in our understanding of how HDL works, just a new knowledge that artificially created HDL is not as effective as naturally occurring HDL.

    We'll see about the LDL I suppose.
     
    avatar
    billh99 replied to iride6606's response:
    One important thing to remember is that in both of these trails they where already treated with statins to a low LDL level (70 in Aim-High).

    What these trails show is that added Niaspan does not add anything ABOVE statin treatment to goals.

    From earlier trails there are still some indications that crystal niacin has a benefit in those can't tolerate statins.
     
    avatar
    billh99 replied to billh99's response:
    I just saw this tweet.

    Michael Davidson MD "00F@mdavidsonmd HPS2 THRIVE is another example of a trial in which the patient population do not benefit. The Baseline LDL 63, TG 120 and HDL 44. Why treat?



    Featuring Experts

    There are no Expert stories for this community right now

    Helpful Tips

    Task Force Recommends Statins for Adults Under 75 With Risk Factors
    Low- to moderate-dose statins should be used by patients at risk for CVD who are between the ages of 40 and 75 years, according to draft ... More
    Was this Helpful?
    0 of 0 found this helpful

    Related Drug Reviews

    • Drug Name User Reviews

    Report Problems With Your Medications to the FDA

    FDAYou are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.